`
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________
`
`ARGENTUM PHARMACEUTICALS LLC
`Petitioner
`v.
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.
`Patent Owner
`
`Patent No. RE38,551
`Issue Date: July 6, 2004
`Title: ANTICONVULSANT ENANTIOMERIC AMINO ACID
`DERIVATIVES
`_______________
`
`Inter Partes Review No. IPR2016-00204
`
`____________________________________________________________
`
`PETITIONER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`
`Petitioner’s
`Ex. No.
`
`Exhibit Name
`
`1001
`1002
`1003
`1004
`1005
`1006
`1007
`1008
`
`1009
`
`1010
`
`1011
`
`1012
`
`1013
`
`1014
`
`U.S. Patent No. RE38,551 (“the ’551 patent”)
`Declaration of Dr. Binghe Wang
`Declaration of Dr. Clayton Heathcock from IPR2014-01126
`Joint Statement of Uncontested Facts
`U.S. Patent No. 5,773,475 (“the ’475 Patent”)
`Excerpt from U.S. Patent Application No. 08/818,688
`District Court Claim Construction Opinion
`Philippe LeGall, 2-Substituted-2-acetamido-N-benzylacetamides.
`Synthesis, Spectroscopic and Anticonvulsant Properties (Dec. 1987)
`(“LeGall”)
`U.S. Patent No. 5,378,729 (“the ’729 Patent”)
`
`Choi et al., Trimethylsilyl Halides: Effective Reagents for the
`Synthesis of β-Halo Amino Acid Derivatives, Tet. Lett., Vol. 36(39),
`pg. 7011 (1995) (“Choi 1995”)
`Purdie et al., The Alkylation of Sugars, J.A.C.S.Vol. 83, pg. 1021
`(1903) (“Purdie”)
`Kohn et al., Preparation and Anticonvulsant Activity of a Series of
`Functionalized α-Heteroatom-Substituted Amino Acids, J. Med.
`Chem. Vol. 34, pg. 2444 (1991) (“Kohn 1991”)
`Silverman, R. B., The Organic Chemistry of Drug Design and Drug
`Action, Academic Press (1992) (“Silverman”)
`Development of New Stereoisomeric Drugs, U.S. F.D.A., May 1,
`1992
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`1020
`1021
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`1027
`1028
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Cortes et al., Effect of Structural Modification of the Hydantoin Ring
`on Anticonvulsant Activity, J. Med. Chem., Vol. 28, pg. 601 (1985)
`(“Cortes 1985”)
`LeGall et al., Synthesis of Functionalized Non-Natural Amino Acid
`Derivatives via Amidoalkylation Transformations, Int. J. Peptide
`Protein Res. Vol. 32, pg. 279 (1988) (“LeGall 1988”)
`Kohn et al., Synthesis and Anticonvulsant Activities of α-Heterocyclic
`α-Acetamido-N-benzylacetamide Derivatives, J. Med. Chem. Vol. 36,
`pg. 3350 (1993)
`Kohn et al., Preparation and Anticonvulsant Activity of a Series of
`Functionalized α-Aromatic and α-Heteroaromatic Amino Acids, J.
`Med. Chem. Vol. 33, pg. 919 (1990)
`U.S. Patent No. 5,654,301 (“the ’301 Patent”)
`Patent Term Extension Request in U.S. Patent No. 5,654,301
`FDA Guideline for Industry, November 1994
`Schmidt, R., Dose-Finding Studies in Clinical Drug Development,
`Eur. J. Clin. Pharmacol, Vol. 34, pg. 15 (1988)
`Isbell, H. S., The Optical Rotation of the Various Asymmetric Carbon
`Atoms in the Hexose and Pentose Sugars, B. S. Jour. Research, Vol.
`5, pg. 1041 (1929)
`Wilson and Gisvold’s Textbook of Organic Medicinal Chemistry,
`Physicochemical Properties in Relation to Biologic Action, (Delgado
`J. N. & Remers W. A., eds. 1991) (Wilson)
`Thornber, C. W., Isosterism and Molecular Modification in Drug
`Design, Chem. Soc. Rev., Vol. 8(4) (1979)
`Reissue Declaration in Reissue of U.S. Patent No. 5,773,475
`Subpoena directed to The University of Houston
`Texas Public Information Act Requests and Responses
`3
`
`
`
`1029
`
`1030
`
`1031
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`1037
`1038
`
`1039
`
`1040
`1041
`1042
`1043
`
`
`
`
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Zhou et al., Decisions under Uncertainty: the Fuzzy Compromise
`Decision Support Problem, Eng. Opt. Vol. 20, pg. 21 (1992)
`Mistree et al., A Decsion-Based Perspective for the Design of
`Methods for Systems Design, (1989)
`Mistree et al., A Decision-based Approach to Concurrent Design,
`Concurrent Engineering: Contemporary Issues and Modern Design
`Tools, (Parsaei, H. R. & Sullivan W. G. Eds. 1993)
`Ingram W. T., Concerning Periodic Points in Mappings of Continua,
`J. Am. Math. Soc., Vol. 104(2) (1988)
`Mattson, Current Challenges in the Treatment of Epilepsy,
`Neurology, Vol. 44(suppl. 5), pg. 84 (1994)
`Löscher et al., New Avenues for Anti-Epileptic Drug Discovery and
`Development, Nature Reviews: Drug Discovery, Vol. 12, pg. 12
`(2013)
`Cohen authorized amendment in U.S. Patent Application No.
`08/818,688
`Substitute Petition
`Marked-up Petition
`December 22, 2015 Email from M. Dowd to A. Reister, J. Robbins,
`and R. Longton.
`January 4, 2016 Email from M. Dowd to A. Reister, J. Robbins, and
`R. Longton.
`February 19, 2016 Email from M. Dowd to A. Reister.
`February 25, 2016 Letter from M. Dowd to A. Reister.
`February 25, 2016 Letter from M. Dowd to A. Reister.
`March 18, 2016 Email from M. Dowd to A. Reister.
`
`4
`
`
`
`1044
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Docket for UCB Inc. et al v. Accord Healthcare Inc. et al, Case No.
`1:13-cv-01206-LPS (Dist. Del.).
`
`Respectfully Submitted,
`
`Dated: April 14, 2016
`
`
`
`By:
`
`/Matthew J. Dowd/
`
`Matthew J. Dowd
`Reg. No. 47,534
`Justin W. Crotty
`Reg. No. 68,937
`ANDREWS KURTH LLP
`1350 I Street, NW
`Suite 1100
`Washington, DC 20005
`Phone: (202) 662-2701
`Fax: (202) 974-9511
`MatthewDowd@andrewskurth.com
`
`
`
`5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`
`The undersigned hereby certifies that a copy of the above-captioned
`Petitioner’s Updated Exhibit List will be served on April 14, 2016 via e-mail and
`Federal Express or similar overnight service to the attorney(s) of record for the
`patent at the addresses below:
`
`
`areister@cov.com
`jrobbins@cov.com
`rlongton@cov.com
`
`Covington & Burling LLP
`One City Center, 850 Tenth Street, NW
`Washington, DC 20001
`
`By:
`
`/Matthew J. Dowd/
`
`Matthew J. Dowd
`Reg. No. 47,534
`ANDREWS KURTH LLP
`1350 I Street, NW
`Suite 1100
`Washington, DC 20005
`Phone: (202) 662-2701
`Fax: (202) 974-9511
`MatthewDowd@andrewskurth.com